500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
News | 2024-11-08
Phase 2a study initiated
The primary objective of the study - also referred to as a Proof of Concept - is to evaluate the efficacy of LIB-01 in patients with erectile dysfunction.
Read More >Dicot Pharma to Nasdaq First North 2024-11-06
News | 2024-12-19
Important patent family approved in the US
The three patents in the family, now fully approved, strengthen both product and method protection until 2042 in the US.
Read More >
The global market for treating sexual dysfunctions is annually worth around 8 billion USD and will increase due to underlying causes such as growing number of elderly
Today's potency drugs were launched over twentyfive years ago and have limitations
Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped
Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 show effect during at least 28 days
Sexual medicine experts states that there is a great need for new potency drugs
In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma
The ambition with LIB-01
- Longer duration
- Effective for everyone
- Minimal side-effects
